Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

TEVA Teva Pharmaceutical Industries Ltd

13,19

0,18 (1,38%)

Nach Börsenschluss

Zuletzt aktualisiert: 22:37:14

Verzögert um 15 Minuten

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
d395544dars.pdf

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

News Teva Pharmaceutical Industries Ltd

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Dienstag 16 April 2024 (1 Woche vor) • Business Wire

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Dienstag 16 April 2024 (1 Woche vor) • GlobeNewswire Inc.

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Dienstag 16 April 2024 (1 Woche vor) • Business Wire

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Donnerstag 11 April 2024 (2 Wochen vor) • Business Wire

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Dienstag 9 April 2024 (2 Wochen vor) • Business Wire

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
Samstag 6 April 2024 (3 Wochen vor) • Business Wire

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Donnerstag 4 April 2024 (3 Wochen vor) • Business Wire

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
Montag 1 April 2024 (3 Wochen vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Teva Pharmaceutical Industries Ltd News-Artikel

Deutsche Telekom (QX)

Euro vs US Dollar

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen